The action of ovarian hormones in cardiovascular disease

Rodolfo A. Medina, Evelyn Aranda, Cesar Verdugo, Sumie Kato, Gareth I. Owen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year, after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the literature to piece together the physiological actions of estrogen and progesterone preparations on the individual mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the roles played by hormones on the short- and long-term risks of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)325-341
Number of pages17
JournalBiological Research
Volume36
Issue number3-4
StatePublished - 2003
Externally publishedYes

Fingerprint

cardiovascular diseases
Cardiovascular Diseases
hormones
Hormones
estrogens
hormone replacement therapy
Estrogens
Progesterone
myocardial infarction
progesterone
Hormone Replacement Therapy
risk factors
Myocardial Infarction
incidence
Incidence
Contraceptives, Oral, Combined
fibrinolysis
oral contraceptives
cardioprotective effect
thrombosis

Keywords

  • Atherosclerosis cardiovascular disease
  • Estrogen
  • Hormone replacement therapy (HRT)
  • Myocardial infarction
  • Oral contraceptives
  • Progestins
  • Venous thrombosis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Medina, R. A., Aranda, E., Verdugo, C., Kato, S., & Owen, G. I. (2003). The action of ovarian hormones in cardiovascular disease. Biological Research, 36(3-4), 325-341.

The action of ovarian hormones in cardiovascular disease. / Medina, Rodolfo A.; Aranda, Evelyn; Verdugo, Cesar; Kato, Sumie; Owen, Gareth I.

In: Biological Research, Vol. 36, No. 3-4, 2003, p. 325-341.

Research output: Contribution to journalArticle

Medina, RA, Aranda, E, Verdugo, C, Kato, S & Owen, GI 2003, 'The action of ovarian hormones in cardiovascular disease', Biological Research, vol. 36, no. 3-4, pp. 325-341.
Medina RA, Aranda E, Verdugo C, Kato S, Owen GI. The action of ovarian hormones in cardiovascular disease. Biological Research. 2003;36(3-4):325-341.
Medina, Rodolfo A. ; Aranda, Evelyn ; Verdugo, Cesar ; Kato, Sumie ; Owen, Gareth I. / The action of ovarian hormones in cardiovascular disease. In: Biological Research. 2003 ; Vol. 36, No. 3-4. pp. 325-341.
@article{b019126907ff43beb2892b0a4f8394ce,
title = "The action of ovarian hormones in cardiovascular disease",
abstract = "The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year, after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the literature to piece together the physiological actions of estrogen and progesterone preparations on the individual mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the roles played by hormones on the short- and long-term risks of cardiovascular disease.",
keywords = "Atherosclerosis cardiovascular disease, Estrogen, Hormone replacement therapy (HRT), Myocardial infarction, Oral contraceptives, Progestins, Venous thrombosis",
author = "Medina, {Rodolfo A.} and Evelyn Aranda and Cesar Verdugo and Sumie Kato and Owen, {Gareth I.}",
year = "2003",
language = "English (US)",
volume = "36",
pages = "325--341",
journal = "Biological Research",
issn = "0716-9760",
publisher = "Society of Biology of Chile",
number = "3-4",

}

TY - JOUR

T1 - The action of ovarian hormones in cardiovascular disease

AU - Medina, Rodolfo A.

AU - Aranda, Evelyn

AU - Verdugo, Cesar

AU - Kato, Sumie

AU - Owen, Gareth I.

PY - 2003

Y1 - 2003

N2 - The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year, after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the literature to piece together the physiological actions of estrogen and progesterone preparations on the individual mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the roles played by hormones on the short- and long-term risks of cardiovascular disease.

AB - The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year, after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the literature to piece together the physiological actions of estrogen and progesterone preparations on the individual mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the roles played by hormones on the short- and long-term risks of cardiovascular disease.

KW - Atherosclerosis cardiovascular disease

KW - Estrogen

KW - Hormone replacement therapy (HRT)

KW - Myocardial infarction

KW - Oral contraceptives

KW - Progestins

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0242456285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242456285&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 325

EP - 341

JO - Biological Research

JF - Biological Research

SN - 0716-9760

IS - 3-4

ER -